J B Delmotte1, H Beaussier2, N Auzeil3, F Massicot3, O Laprévote3, E Raymond4, F Coudoré5. 1. Clinical Research Center, Paris Saint Joseph Hospital, 185 rue Raymond Losserand, Paris, France. Electronic address: jeanbaptiste.delmotte@aphp.fr. 2. Clinical Research Center, Paris Saint Joseph Hospital, 185 rue Raymond Losserand, Paris, France. 3. UMR8638, Sorbonne Paris Cité University, Faculty of Pharmacy, Paris, France. 4. Oncology Department, Paris Saint Joseph Hospital, Paris, France. 5. CESP/INSERM UMR-S 1178, Paris-Sud Saclay University, Faculty of Pharmacy, Châtenay-Malabry, France; Biology Unit, Paris Saint Joseph Hospital, Paris, France.
Abstract
PURPOSE: To better understand how quantitative sensory testing could help the clinician in the management of oxaliplatin-induced peripheral neuropathy in terms of earlier and more reliable detection, we conducted a two-year prospective study. METHODS: Thermal sensory assessment, tactile sensory assessment, neuropathic pain assessment and adverse events gradation (NCI-CTC) were performed during treatment and 6 months after treatment completion. RESULTS: 35 patients were enrolled and followed-up during one year. Cold and Warm Detection Thresholds were higher 6 months after treatment completion than at enrollment. Mechanical detection thresholds didn't change significantly. Neurotoxicity was mostly grade-1, only 18% grade-2 and no grade-3. Grade-2 patients received lower oxaliplatin cumulative dose than grade-1, which reveals effective dose adaptation and grade-2 patients were more likely to develop painful neuropathy. CONCLUSION: Thermal thresholds impairment emerges too late to help the clinician in the prophylaxis of neuropathy. Management of OXA-treatment based on NCI-CTC, as currently recommended, remains the best way to detect neuropathy and ensure treatment adaptation.
PURPOSE: To better understand how quantitative sensory testing could help the clinician in the management of oxaliplatin-induced peripheral neuropathy in terms of earlier and more reliable detection, we conducted a two-year prospective study. METHODS: Thermal sensory assessment, tactile sensory assessment, neuropathic pain assessment and adverse events gradation (NCI-CTC) were performed during treatment and 6 months after treatment completion. RESULTS: 35 patients were enrolled and followed-up during one year. Cold and Warm Detection Thresholds were higher 6 months after treatment completion than at enrollment. Mechanical detection thresholds didn't change significantly. Neurotoxicity was mostly grade-1, only 18% grade-2 and no grade-3. Grade-2 patients received lower oxaliplatin cumulative dose than grade-1, which reveals effective dose adaptation and grade-2 patients were more likely to develop painful neuropathy. CONCLUSION: Thermal thresholds impairment emerges too late to help the clinician in the prophylaxis of neuropathy. Management of OXA-treatment based on NCI-CTC, as currently recommended, remains the best way to detect neuropathy and ensure treatment adaptation.
Authors: Daniel L Hertz; Travis J Dockter; Daniel V Satele; Charles L Loprinzi; Jennifer Le-Rademacher Journal: Support Care Cancer Date: 2021-06-27 Impact factor: 3.603